Table 2.
Included articles demonstrating abscopal effect
| Study | Year | True defined* | Sex | Age | Cancer type | RT to primary | RT to metastasis | RT at multiple sites | RT total dose (Gy) | RT fx | Average RT dose/fx (Gy) | BED | RT only | RT + surgery | RT + chemotherapy | RT + IT | Follow- up time (mo) | Outcome | New met |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cotter et al74 | 2011 | Y | M | 70 | 39 | N | Y | N | 12 | 2 | 6 | 19.2 | Y | N | N | N | 25 | Alive | Y |
| Ebner et al69 | 2017 | Y | M | 75 | 13 | N | Y | N | 73.6 | 16 | 4.6 | 107 | Y | N | N | N | 46 | Dead | Y |
| Y | M | 85 | 13 | N | Y | N | 50.4 | 12 | 4.2 | 71.5 | Y | N | N | N | 92 | Alive | N | ||
| Fairlamb66 | 1981 | Y | F | 73 | 23 | N | Y | N | 40 | 15 | 2.7 | 50.6 | Y | N | N | N | 56 | Alive | Y |
| Golden et al72 | 2013 | Y | M | 64 | 41 | N | Y | N | 30 | 5 | 6 | 48 | N | N | N | Y | 10 | Alive | Y |
| Antoniades et al73 | 1977 | Y | M | 44 | 55 | Y | N | N | 30 | 20 | 1.5 | 34.5 | Y | N | N | N | - | Alive | N |
| Y | M | 40 | 55 | Y | N | N | 30 | 20 | 1.5 | 34.5 | Y | N | N | N | - | Alive | N | ||
| Cong et al68 | 2017 | Y | F | 64 | 41 | Y | N | N | 37.5 | 5 | 7.5 | 65.6 | N | N | N | Y | - | Alive | N |
| Desar et al67 | 2016 | Y | M | 19 | 47 | N | Y | N | 30 | 10 | 3 | 39 | Y | N | N | N | 6 | Dead | Y |
| Joe et al61 | 2017 | Y | F | 57 | 14 | Y | Y | Y | 54 | 30 | 1.8 | 63.7 | N | N | Y | N | 48 | Alive | N |
| Lakshmanagowda et al59 | 2009 | Y | F | 65 | 55 | Y | N | N | 24 | 12 | 2 | 28.8 | Y | N | N | N | 6 | Alive | N |
| MacManus et al58 | 1994 | Y | M | 58 | 23 | Y | N | N | 20 | 10 | 2 | 24 | Y | N | N | N | 9 | Dead | N |
| Nam et al44 | 2005 | Y | M | 65 | 21 | N | Y | N | 30 | - | - | - | Y | N | N | N | 15 | Alive | N |
| Ohba et al56 | 1998 | Y | M | 76 | 21 | N | Y | N | 36 | - | - | - | Y | N | N | N | 25 | Alive | N |
| Okuma et al55 | 2011 | Y | M | 63 | 21 | N | Y | N | 60.8 | 27 | 2.2 | 74.4 | Y | N | N | N | 54 | Alive | N |
| Postow et al70 | 2012 | Y | F | 33 | 25 | N | Y | N | 28.5 | 3 | 9.5 | 55.5 | N | N | N | Y | 10 | Alive | N |
| Rees and Ross52 | 1983 | Y | M | 49 | 16 | Y | N | N | 40 | 20 | 2 | 48 | Y | N | N | N | 20 | Dead | - |
| Robins et al51 | 1981 | Y | F | 59 | 55 | N | Y | N | 20 | 10 | 2 | 24 | Y | N | N | N | 4 | Dead | Y |
| Stamell et al71 | 2012 | Y | M | 67 | 25 | Y | N | N | 24 | 3 | 8 | 43.2 | Y | N | N | N | 84 | Alive | Y |
| Takaya et al46 | 2007 | Y | F | 69 | 10 | Y | N | Y | 22 | 10 | 2.2 | 26.8 | Y | N | N | N | 12 | Alive | N |
| Wersäll et al45 | 2009 | Y | F | 83 | 23 | Y | N | N | 32 | 4 | 8 | 57.6 | Y | N | N | N | - | Alive | N |
| Y | F | 64 | 23 | N | Y | N | - | - | - | - | N | N | Y | N | 54 | Alive | N | ||
| Y | M | 69 | 23 | N | Y | N | 30 | 2 | 15 | 75 | Y | N | N | N | 24 | Alive | Y | ||
| Y | F | 55 | 23 | Y | N | N | 32 | 4 | 8 | 57.6 | Y | N | N | N | - | Alive | N | ||
| Sullivan et al48 | 2013 | Y | M | 68 | 25 | N | Y | N | - | - | - | - | N | N | N | N | 13 | Alive | N |
| Hiniker et al65 | 2012 | Y | - | - | 25 | N | Y | N | - | - | - | - | N | N | N | Y | - | Alive | N |
| Isobe et al63 | 2009 | N | F | 65 | 55 | N | N | N | 40 | - | - | - | N | N | N | N | 60 | Alive | N |
| Joe et al61 | 2018 | Y | M | 74 | 16 | Y | Y | Y | 30 | 10 | 3 | 39 | Y | N | N | N | 14 | Alive | N |
| Kodama et al60 | 2013 | Y | M | 74 | 41 | N | Y | Y | 48 | 24 | 2 | 57.6 | N | N | N | Y | 61 | Dead | Y |
| Nakanishi et al57 | 2008 | Y | M | 79 | 21 | Y | N | N | 48 | 1 | 48 | 278 | Y | N | N | N | - | Alive | N |
| Okwan-Duodu et al54 | 2015 | Y | F | 50 | 25 | N | Y | N | - | - | - | - | N | Y | N | Y | 20 | Alive | Y |
| Hamilton et al25 | 2018 | Y | M | 47 | 41 | N | Y | N | 25 | 5 | 5 | 37.5 | N | Y | N | N | 7 | Alive | N |
| Gutkin et al38 | 2018 | Y | M | 57 | 25 | N | Y | N | 54 | 3 | 18 | 151 | N | N | N | Y | 78 | Alive | Y |
| Chino et al40 | 2018 | Y | M | 58 | 41 | N | Y | N | 60 | 8 | 7.5 | 105 | Y | N | N | N | 18 | Alive | N |
| Leung et al34 | 2018 | Y | F | 65 | 7 | Y | Y | Y | 225 | 15 | 15 | 562 | Y | N | N | N | 60 | Alive | N |
| Sperduto et al28 | 2017 | Y | F | 36 | 25 | N | Y | Y | 25 | 5 | 5 | 37.5 | N | Y | Y | N | 120 | Alive | N |
| Van de Walle et al24 | 2016 | Y | F | 66 | 23 | N | Y | N | 39 | 13 | 3 | 50.7 | Y | N | N | N | 17 | Alive | Y |
| Zhao et al23 | 2018 | Y | M | 65 | 16 | N | Y | N | 42 | 6 | 7 | 71.4 | Y | N | N | N | 15 | Alive | N |
| Katayama et al33 | 2017 | Y | M | 63 | 41 | N | Y | Y | 45 | 15 | 3 | 58.5 | Y | N | N | N | 9 | Alive | N |
| Britschgi et al41 | 2018 | Y | M | 47 | 41 | N | Y | N | 18 | 3 | 6 | 28.8 | N | N | N | Y | 24 | Alive | N |
| Kim and Kim35 | 2019 | Y | M | 70 | 21 | Y | N | N | 48 | 4 | 12 | 105 | N | Y | N | N | 21 | Alive | N |
| Bitran42 | 2019 | Y | F | 62 | 41 | Y | N | N | 27 | 9 | 3 | 35.1 | N | N | N | Y | 54 | Alive | N |
| Shinde et al29 | 2019 | Y | M | 75 | 20 | Y | N | Y | 14.8 | 2 | 7.4 | 25.7 | N | N | N | Y | 10 | Alive | N |
| Lin et al32 | 2019 | Y | M | 71 | 41 | N | Y | N | 48 | 8 | 6 | 76.8 | Y | N | N | N | 19 | Alive | Y |
| Brenneman et al36 | 2019 | Y | F | 67 | 47 | Y | N | N | 50 | 25 | 2 | 60 | Y | N | N | N | 18 | Alive | N |
| Sato et al31 | 2016 | Y | M | 54 | 18 | Y | N | N | 48 | 24 | 2 | 57.6 | N | N | N | Y | 5 | Dead | Y |
| Shi et al27 | 2017 | Y | F | 67 | 43 | Y | N | N | 45 | 15 | 3 | 58.5 | N | Y | N | N | 1 | Dead | N |
| Hidaka et al37 | 2017 | Y | M | 88 | 55 | Y | N | Y | 32 | 8 | 4 | 44.8 | Y | N | N | N | 6 | Dead | N |
| Barsky et al39 | 2019 | Y | M | 67 | 24 | Y | N | N | 30 | 10 | 3 | 39 | N | N | Y | N | 7 | Dead | N |
| Siva et al49 | 2013 | Y | F | 78 | 41 | Y | N | Y | 60 | 30 | 2 | 72 | Y | N | N | N | 2 | Alive | Y |
| Ishiyama et al64 | 2012 | Y | M | 61 | 23 | N | Y | Y | 18 | 1 | 18 | 50.4 | Y | N | N | N | 34 | Alive | Y |
| Poon and Wong53 | 2017 | Y | M | 79 | 45 | N | Y | Y | 24 | 4 | 6 | 38.4 | Y | N | N | N | 6 | Alive | N |
| Azami et al43 | 2018 | Y | F | 64 | 7 | Y | Y | Y | 60 | 30 | 2 | 72 | Y | N | N | N | 21 | Alive | N |
| Masue et al75 | 2007 | N | M | 58 | 23 | N | N | N | - | - | - | - | N | N | N | N | 46 | Alive | N |
| Agyeman et al76 | 2019 | Y | M | 56 | 47 | Y | N | N | 40 | 20 | 2 | 48 | Y | N | N | N | 17 | Alive | N |
Abbreviations: BED = biologically effective dose, assuming an α:β ratio of 10; fx = fraction; IT = immunotherapy; met = metastasis; RT = radiation therapy.
⁎
Refers to whether or not the article demonstrates a true abscopal response (as defined by the result of any local therapy affecting a distant, untreated tumor).